Priralfinamide

DB06649InvestigationalSmall molecule

Investigated for use/treatment in pain (acute or chronic).

Mechanism: Pharmacologically active on Amine oxidase [flavin-containing] B, Voltage-dependent N-type calcium channel subunit alpha-1B, and Voltage-gated sodium channel alpha subunit
Curator reviewed
Primary indication: Investigated for use/treatment in pain (acute or chronic).Curator reviewed
Formula / weight: C₁₇H₁₉FN₂O₂ · 302.349 g/mol (avg)
Also known as: Ralfinamide
Code names: NW-1029 · PNU-0154339E

Resolves to

Compound

Structure

InChIKeyBHJIBOFHEFDSAU-LBPRGKRZSA-NSMILESC[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Priralfinamide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.